ArticleDiscover oncology2025
Predictive molecular alterations of prostate cancer brain metastases based on a companion diagnostic assay.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current first-line treatment standard for patients with metastatic prostate cancer (mPCa), is a combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), plus the addition of docetaxel for fit patients with high-volume or high-risk disease. This upfront treatment is highly effective, however, the emergence of acquired resistance is nearly universal, upon which, molecular predictive biomarkers are needed for further targeted therapies. Genomic studies have identified a population of 20-30% prostate cancer (PCa) patients harboring tumor DNA damage repair (DDR) alterations. Recent clinical trials have shown that treatment with PARP inhibitors (PARPi) achieve high response rates in tumors with BRCA1- and BRCA2-pathogenic alterations. Patients with metastatic castration-resistant PCa (mCRPC) harboring these alterations showed the highest overall survival benefit. Prostate cancer brain metastases (PCBM) is a usual exclusion criterion for clinical trials in part due to expected poor outcome. Recent work from our group in Switzerland has shown that 19.6% of patients with prostate cancer brain metastases (PCBM) had genomic alterations in homologous recombination repair (HRR) genes. However, the study was done using a research genomic assay. To maximize clinical relevance, in this work we analyzed 46 men suffering from PCBM from the same cohort using the FDA approved companion diagnostic FoundationOne®CDx assay. We found that 12/44 patients (27.3%), from which a metastatic sample was available, harbored qualifying alterations for PARPi therapy. Additionally, we found 7/44 patients (15.9%) qualifying for immune check-point inhibitors therapy. We anticipate that these findings will improve the rate of molecular testing in mCRPC patients with brain metastases and advance personalized management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.